Login
$REPL
$21.32 -$0.09 (0.42%) After hours

$REPL 8-K SEC Filings

Filed On Filing
28 Oct 2026 8-K: Results of Operations and Financial Condition

TUDRIQEV first delivered to patients for advanced melanoma on October 6th

16 Sep 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REPLIMUNE GROUP, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

14 Aug 2026 8-K: Results of Operations and Financial Condition

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

10 Aug 2026 8-K: Other Events

Pre-Funded Warrants to Purchase 2,736,340 Shares of Common Stock

07 Aug 2026 8-K: Other Events

© 2026 Replimune Group Inc. TUDRIQEV TM (vusolimogene oderparepvec - wtpg ) FDA Accelerated Approval Investor Call August 6, 2026

31 Jul 2026 8-K: Other Events

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

30 Jul 2026 8-K: Regulation FD Disclosure

CC-1 Vusolimogene oderparepvec-wtpg (TUDRIQEV ) in Combination with Nivolumab for the Treatment of Adults with Unresectable Advanced Cutaneous Melanoma July 30, 2026 United States Food and Drug Administration Cellular, Tissue and Gene Th...

29 Jun 2026 8-K: Results of Operations and Financial Condition

Woburn, MA, June 29, 2026 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and y...

26 Jun 2026 8-K: Regulation FD Disclosure

WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Admin...

29 May 2026 8-K: Regulation FD Disclosure

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative commu...

13 Apr 2026 8-K: Regulation FD Disclosure; Other Events

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

03 Feb 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

April 10, 2026 Target Action Date for RP1 in Advanced Melanoma

12 Jan 2026 8-K: Regulation FD Disclosure

© 2026 Replimune Group Inc. JPM 2026 Presentation Click to edit Master title style 1 Click to edit Master text styles Igniting a systemic immune response to cancer with oncolytic immunotherapy January 14, 2026 JPM Healthcare Conference

06 Nov 2025 8-K: Results of Operations and Financial Condition

Woburn, MA, November 6, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter en...

20 Oct 2025 8-K: Other Events

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026

18 Sep 2025 8-K: Regulation FD Disclosure; Other Events

WOBURN, Mass., Sept 18, 2025 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with t...

04 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure

Woburn, MA, Sept. 2, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food and Drug Adm...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Woburn, MA, August 7, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended...

22 Jul 2025 8-K: Regulation FD Disclosure; Other Events

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

24 Jun 2025 8-K: Regulation FD Disclosure

As previously announced, Replimune Group, Inc. (the “Company”) hosted an Investor Day on Tuesday, June 24, 2025 at 10:00 a.m. ET. The audio webcast and accompanying updated investor event presentation deck is available under “Events and ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support